Research Analysts Set Expectations for Incannex Healthcare Limited’s FY2023 Earnings (NASDAQ:IXHL)

Posted by on Jun 5th, 2023

Incannex Healthcare Limited (NASDAQ:IXHL – Get Rating) – Research analysts at Edison Inv. Res issued their FY2023 earnings per share (EPS) estimates for Incannex Healthcare in a research report issued on Thursday, June 1st. Edison Inv. Res analyst A. Aatkar anticipates that the company will earn ($0.01) per share for the year. The consensus estimate for Incannex Healthcare’s current full-year earnings is ($0.01) per share. Edison Inv. Res also issued estimates for Incannex Healthcare’s FY2024 earnings at ($0.01) EPS.

Incannex Healthcare Trading Up 8.6 %

NASDAQ:IXHL opened at $2.03 on Monday. Incannex Healthcare has a fifty-two week low of $1.77 and a fifty-two week high of $7.51. The stock has a fifty day moving average price of $2.08 and a 200-day moving average price of $2.72.

Institutional Investors Weigh In On Incannex Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the company. UBS Group AG acquired a new position in shares of Incannex Healthcare in the 1st quarter valued at approximately $25,000. Jane Street Group LLC acquired a new position in shares of Incannex Healthcare in the 1st quarter valued at approximately $378,000. Finally, OLD Mission Capital LLC acquired a new position in shares of Incannex Healthcare in the 4th quarter valued at approximately $58,000. Institutional investors own 0.07% of the company’s stock.

Incannex Healthcare Company Profile

(Get Rating)

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies in Australia. It offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. The company also develops IHL-42X, which has completed Phase IIa clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis.

Recommended Stories

Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.